Concepedia

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)

X. Wang, Jun Ren, Jie Zhang, Yuwei Yan, Ni Jiang, Jianing Yu, Lei Di, Gyu‐Yong Song, Jun Jia, Xin Zhou,

Clinical & Translational Oncology · 2015 · 44 citations · 26 references

DOI

Concepts

References

26

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation · 2011 · 5.5K citations · Full text

, , +17

Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text

, , +7

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text

, , +11

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

, , +16

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · The Lancet · 2010 · 1.6K citations

, , +13